Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]"

The authors acknowledge that the supplementary and corrected information provided in this Corrigendum is necessary for a full and proper understanding and interpretation of the original article. New figures and tables are added, and a more detailed description of the methodology is added, including key baseline characteristics of the efficacy population (Table 1). All these new contributions are commented and justified in order to provide clarity to the conclusions. The newly added group of figures (Figs. 1-3) describe individual patient curves in the control group and in the two subgroups of patients treated with IVM grouped according to median plasma concentrations of IVM (>and 160) showed that after the comparisons of the mean or median of individual values, higher decay rates and shorter elimination half-lives were observed in the subgroup IVM >160 (Tables 2 and 3). Fig. 4 in this Corrigendum is added as a supplement to Figs. 3 and 4 of the original manuscript in consideration of the instability of medians in small datasets as is the case of our study. This new figure using means and standard deviations is now included and renders equivalent results (Fig 4);therefore, supporting the conclusions expressed in the original article. Peak viral load values used for calculation of individual patient curves are the highest values measured for each patient. The viral decay rate and elimination half-life were calculated from the viral load vs time curve. Following an exponential model and assuming a first order-rate process, the decay rate constant was calculated from the following equation: λ =−2.303.S where λ is the decay rate constant and S is the slope. Values of 0.01 in log conversion were used for undetectable viral loads. The elimination half-life was calculated as: 0.693/ λ These additions to the original article contribute to clarify and further justify the approach taken for the analysis of the efficacy data through the description of working definitions, provision of individual patient data and incorporation of data analysis less susceptible of providing biased results and conclusions. With all these changes and additions that confirm and support the original article and do not affect the overall conclusions, we seek to provide all the necessary transparency and clarity to readers of the Journal. The clinical relevance of our findings is yet to be defined. Other corrections: The subsection 3.1, titled “3.1. Data are mean (SD). Day-1 indicates baseline measurements” is a misprint and should be omitted. The statement “Data are mean (SD). Day-1 indicates baseline measurements” corresponds to the legend of Fig. 2 of the original article. In the sixth paragraph of the Results section, (Fig. 4a) is incorrect, it should state (Fig. 4). In the sixth paragraph o the Discussion section, the sentence “As it has been proposed in an influenza model of antiviral candidate drugs evaluation25”, should omit the “25” in superindex. We apologize for these errors. © 2021 The Authors